« Genzyme's Termeer on Road to Perdition? | Main | CHO Genome Sequencing Underway - How Close? »

05/15/2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0133edb12831970b

Listed below are links to weblogs that reference Brief Biopharm & Cell engineering History - ECI's CCEXII:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

Dennis Conrad

I think that the problem is recognized in general terms. It has always been there, but I see no one focusing on it. As usual the big biotechs probably deal with this stuff at the proprietary level. The smaller biotech's are at the mercy of the industry. They may witness the problems at the product quality level, but they have no mechanism to drive the cell culture industry towards a solution. No one is listening.

Bruce Lehr

Thanks for the comments Dennis. If there was any doubt in the past (there was) as to the relative importance of protein quality issues, I think those will really jump to the fore now between large increases in productivity and the advent of biosimilars. What two factors are going to put spotlight on protein quality any more than those?

Dennis Conrad

Hi Bruce,

I've been saying this for several years. Cell culture needs to understand and focus on the factors that drive product quality. Much is known but much is ignored by the producers of cell culture products. Product quality starts at the upstream level, not the dowsstream level.

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

April 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada